Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit

被引：17
作者：
Zhou, Shuqin [1 ,2 ]
Skaar, Debra J. [2 ]
Jacobson, Pamala A. [2 ]
Huang, R. Stephanie [2 ]
机构：
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Emergency & Crit Care Med, Shanghai, Peoples R China
[2] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
来源：
FRONTIERS IN PHARMACOLOGY | 2018年 / 9卷
关键词：
pharmacogenomics; personalized medicine; pharmacogenetics; intensive care unit; adverse drug reaction; IMPLEMENTATION CONSORTIUM GUIDELINES; ADVERSE DRUG-REACTIONS; CATECHOL-O-METHYLTRANSFERASE; GUIDED ANTIPLATELET THERAPY; GENETIC-POLYMORPHISM; IN-VITRO; PLASMA-CONCENTRATIONS; CYP2C19; GENOTYPE; INDUCED MYOPATHY; CANCER-PATIENTS;
D O I：
10.3389/fphar.2018.01436
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In the intensive care unit (ICU) setting, where highly variable and insufficient drug efficacies, as well as frequent and unpredictable adverse drug reactions (ADRs) occur, pharmacogenomics (PGx) offers an opportunity to improve health outcomes. However, PGx has not been fully evaluated in the ICU, partly due to lack of knowledge of how genetic markers may affect drug therapy. To fill in this gap, we conducted a review to summarize the PGx information for the medications commonly encountered in the ICU.
引用
收藏
页数：15
相关论文
共 143 条
  • [31] Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy
    Couvert, Philippe
    Giral, Philippe
    Dejager, Sylvie
    Gu, Jessie
    Huby, Thierry
    Chapman, M. John
    Bruckert, Eric
    Carrie, Alain
    [J]. PHARMACOGENOMICS, 2008, 9 (09) : 1217 - 1227
  • [32] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
    Crews, K. R.
    Gaedigk, A.
    Dunnenberger, H. M.
    Leeder, J. S.
    Klein, T. E.
    Caudle, K. E.
    Haidar, C. E.
    Shen, D. D.
    Callaghan, J. T.
    Sadhasivam, S.
    Prows, C. A.
    Kharasch, E. D.
    Skaar, T. C.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) : 376 - 382
  • [33] Human Genetic Variability Contributes to Postoperative Morphine Consumption
    De Gregori, Manuela
    Diatchenko, Luda
    Ingelmo, Pablo M.
    Napolioni, Valerio
    Klepstad, Pal
    Belfer, Inna
    Molinaro, Valeria
    Garbin, Giulia
    Ranzani, Guglielmina N.
    Alberio, Giovanni
    Normanno, Marco
    Lovisari, Federica
    Somaini, Marta
    Govoni, Stefano
    Mura, Elisa
    Bugada, Dario
    Niebel, Thekla
    Zorzetto, Michele
    De Gregori, Simona
    Molinaro, Mariadelfina
    Fanelli, Guido
    Allegri, Massimo
    [J]. JOURNAL OF PAIN, 2016, 17 (05) : 628 - 636
  • [34] Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers
    de Leon, J
    Dinsmore, L
    Wedlund, P
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) : 420 - 421
  • [35] Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
    Deiman, B. A. L. M.
    Tonino, P. A. L.
    Kouhestani, K.
    Schrover, C. E. M.
    Scharnhorst, V.
    Dekker, L. R. C.
    Pijls, N. H. J.
    [J]. NETHERLANDS HEART JOURNAL, 2016, 24 (10) : 589 - 599
  • [36] Clinical significance of the cytochrome P4502C19 genetic polymorphism
    Desta, Z
    Zhao, XJ
    Shin, JG
    Flockhart, DA
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (12) : 913 - 958
  • [37] DeVane C Lindsay, 2003, Psychopharmacol Bull, V37 Suppl 2, P25
  • [38] Preventable and non-preventable risk factors for adverse drug events related to hospital admissions in the elderly - A prospective study
    Doucet, J
    Jego, A
    Noel, D
    Geffroy, CE
    Capet, C
    Coquard, A
    Couffin, E
    Fauchais, AL
    Chassagne, P
    Mouton-Schleifer, D
    Bercoff, E
    [J]. CLINICAL DRUG INVESTIGATION, 2002, 22 (06) : 385 - 392
  • [39] Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy
    Empey, Philip E.
    Stevenson, James M.
    Tuteja, Sony
    Weitzel, Kristin W.
    Angiolillo, Dominick J.
    Beitelshees, Amber L.
    Coons, James C.
    Duarte, Julio D.
    Franchi, Francesco
    Jeng, Linda J. B.
    Johnson, Julie A.
    Kreutz, Rolf P.
    Limdi, Nita A.
    Maloney, Kristin A.
    Obeng, Aniwaa Owusu
    Peterson, Josh F.
    Petry, Natasha
    Pratt, Victoria M.
    Rollini, Fabiana
    Scott, Stuart A.
    Skaar, Todd C.
    Vesely, Mark R.
    Stouffer, George A.
    Wilke, Russell A.
    Cavallari, Larisa H.
    Lee, Craig R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (04) : 664 - 674
  • [40] Genetic predisposition to adverse drug reactions in the intensive care unit
    Empey, Philip E.
    [J]. CRITICAL CARE MEDICINE, 2010, 38 : S106 - S116
12345678910